Lansen has announced that it expects its profit from operations from its core business to show a noticeable decrease as compared to that in 2014. In addition, Lansen recorded certain one-off non-operating losses and there was an accounting treatment to recognize an insurance claim income in 2015 which was yet to be determined in its year-end audit. As a result, the net profit of Lansen for the year ended 31 December 2015 is expected to show a relatively substantial decline as compared to that in 2014.

The decrease in Lansen's profitability was mainly attributed to a number of operating factors already taken into account by Cathay in its interim results of 28 August 2015 and its trading update announcement of 29 December 2015. The operating factors were: the decrease in sales of Leflunomide tablets as the product was rebranded from Tuoshu to Hepai; the market launch costs of new products including Fillderm and Bio-Rad diagnostic kits, which resulted in increased operating expenses in 2015 but are expected to contribute to Group earnings in 2016; and realignment of product development and limiting production capacities of its healthcare business.